vanoxerine has been researched along with mdl 100907 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carlsson, ML | 1 |
| Carlsson, A; Carlsson, ML; Martin, P; Nilsson, M; Sorensen, SM; Waters, N; Waters, S | 1 |
| Cathala, A; Drago, F; Leggio, GM; Neny, M; Piazza, PV; Rouge-Pont, F; Spampinato, U | 1 |
3 other study(ies) available for vanoxerine and mdl 100907
| Article | Year |
|---|---|
The selective 5-HT2A receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse--implications for psychosis.
Topics: Animals; Biogenic Monoamines; Disease Models, Animal; Dizocilpine Maleate; Dopamine Uptake Inhibitors; Excitatory Amino Acid Antagonists; Fluorobenzenes; Glutamic Acid; Hallucinogens; Lysergic Acid Diethylamide; Male; Mice; Mice, Inbred Strains; Neurotransmitter Agents; Piperazines; Piperidines; Psychomotor Performance; Psychotic Disorders; Receptor, Serotonin, 5-HT2A; Receptors, Muscarinic; Receptors, Serotonin; Serotonin; Serotonin Antagonists | 1995 |
The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice.
Topics: Amphetamine; Animals; Dizocilpine Maleate; Dopamine; Dopamine Agonists; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Fluorobenzenes; Glutamic Acid; Haloperidol; Hyperkinesis; Male; Mice; Mice, Inbred Strains; Motor Activity; N-Methylaspartate; Piperazines; Piperidines; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Serotonin Antagonists | 1999 |
In vivo evidence that constitutive activity of serotonin2C receptors in the medial prefrontal cortex participates in the control of dopamine release in the rat nucleus accumbens: differential effects of inverse agonist versus antagonist.
Topics: Aminopyridines; Analgesics, Opioid; Animals; Dopamine; Dopamine Antagonists; Dopamine Uptake Inhibitors; Ethylamines; Extracellular Space; Haloperidol; Indoles; Male; Microdialysis; Microinjections; Morphinans; Neural Pathways; Nucleus Accumbens; Piperazines; Prefrontal Cortex; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2C; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Serotonin Receptor Agonists | 2009 |